Drugs / Testosterone Enanthate
Testosterone Enanthate
also known as
Androtardyl · delatestryl · NSC-17591 · Primoteston depot · TEST · Testosterone enantate · Testosterone enanthate ciii · Testosterone enanthate component of ditate-ds · +3 more
Small molecule targets AR via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | DELATESTRYL | — | 1979-08-02 – 1980-02-01 | fda.gov ↗ |
| Approved | US (FDA) | DELATESTRYL | — | 1953-12-24 | fda.gov ↗ |
Trials 27 · a red edge is where a trial was stopped
1952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00878995 Comparator | Jun 2009 → Jun 2014 | hypoproteinemia, hypercatabolic, squamous cell carcinoma | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 1 | NCT01017458 Comparator | Jun 2007 → Aug 2008 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00399165 Comparator | Nov 2006 → May 2007 | — | University of Washington | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02697188 Comparator | Nov 2007 → Apr 2008 | hypogonadism | Clarus Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03674320 Comparator | Dec 2021 → Aug 2024 | chronic obstructive pulmonary disease | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00161304 Comparator | Apr 2003 → Aug 2004 | — | Leonard S. Marks, M.D. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04026880 Comparator | Jan 2021 → Jan 2022 | — | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00493987 Comparator | Nov 2002 → Dec 2009 | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Testosterone Enanthate | “Pharmacokinetic Study of Testosterone Enanthate” NCT01887418 ↗34“testosterone enanthate” NCT04971447 ↗ |
| Known as | Androtardyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | delatestryl | “delatestryl” NCT02248701 ↗ |
| Known as | NSC-17591 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Primoteston depot | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | TEST | “The objective of this study was to determine the effects of weekly testosterone enanthate (TEST; 200 mg·wk -1 ) injections on energy expenditure, energy substrate oxidation,...” PMID 36563086 ↗ Nov 2022 |
| Known as | Testosterone enantate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Testosterone enanthate ciii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Testosterone enanthate component of ditate-ds | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Testosteroni enantas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Xyosted | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Known as | Xyosted (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200335 ↗ |
| Action | Activate | “Androgen Receptor agonist” CHEMBL1200335 ↗ |
| Modality | Small molecule | — CHEMBL1200335 ↗ |
| Route | Intramuscular | “testosterone enanthate or matching placebo intramuscularly” PMID 17105798 ↗ Nov 2006 |
| Target | AR | “Androgen Receptor agonist” CHEMBL1200335 ↗ |